Humanized mice (target-specific)

The genO‑hPD‑1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

The genO‑hPD‑1/hPD‑L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

The genO‑hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

The genO‑hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint OX40 in fully immunocompetent mice.

The genO‑hSTING mouse enables the in vivo assessment of agents and therapies targeting the human STING in fully immunocompetent mice.

The genO‑hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

hCD137 immunocompetent mice enable the efficacy assessment of anti-CD137

‍

genO‑panhCD3 immunocompetent mice enable the efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

‍

genO‑hCD3ε immunocompetent mice enable the preclinical in vivo efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

The fully immunocompetent genO‑hTFRC mouse model enables in vivo efficacy assessment and profiling of compounds targeting human TFRC (CD71, TfR1) and aiming to deliver therapeutic agents through the blood brain barrier.

The genO‑hPD‑1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

Double humanized genO‑HSA/hFcRn mouse model as a cutting-edge platform for preclinical development of HSA and FcRn-oriented therapeutics.

The hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

The genO-hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Use the hIgE/hFcεR1 mouse model to successfully screen for innovative therapeutics for allergy, asthma and other IgE-mediated diseases.

The hPD-1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

The hPD-1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

Preclinical hGLP-1R model for assessment of agents targeting human GLP-1R

Preclinical humanized Fc-gamma receptor (hFcγR) model enabling the assessment of Fc receptor pathways targeted therapies.

‍

The hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

The hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

The hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

The human CD4 mouse model allows in vivo efficacy and safety assessment of anti-human CD4 compounds.

‍

The hTNF-α model provides new opportunities for assessment of anti-TNF therapies.

This upgraded, immunocompromised Rag1^-/- version of our HSA/hFcRn mouse model allows the assessment of compounds' half-life and anti-tumor efficacy in a human tumor model.

hCD3ε  immunocompetent mice enable the efficacy assessment of T-cell engagers, to  study cancer cell recognition, immunosuppressant therapies, etc.

The hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

The hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

The hcGAS mouse enables the in vivo assessment of agents and therapies targeting the cGAS–STING cytosolic DNA sensing pathway in fully immunocompetent mice.